Clinical Trials
12 trialsNCT06966700 2026-06-01
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02488967 2026-05-06
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04335669 2025-09-12
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital
Phase 3 Active not recruiting
NCT06795503 2025-01-28
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
Fudan University
Phase 3 Not yet recruiting
NCT03498716 2024-08-21
IMpassion030
Hoffmann-La Roche
Phase 3 Terminated
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT02032277 2021-01-20
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
AbbVie
Phase 3 Completed
NCT04301739 2020-03-12
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Shanghai Henlius Biotech
Phase 3 Not yet recruiting
NCT03876886 2019-03-21
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
ChineseAMS
Phase 3 Unknown
NCT00022516 2016-09-16
22-00
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT01378533 2011-12-28
The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
ChineseAMS
Phase 3 Unknown